Table 5 Issues influencing community pharmacy palliative medicines provision
How frequently do you: | |||||
|---|---|---|---|---|---|
Never | Rarely | Sometimes | Often | Always | |
Undertake medicines optimisation reviews for palliative care patients | 61 (28) | 65 (30) | 52 (24) | 26 (12) | 13 (6.0) |
Feel that lack of awareness of patients’ palliative status influences your ability to help patients access medicines | 13 (6.0) | 22 (10) | 71 (33) | 87 (40) | 25 (11) |
Encounter a discrepancy between palliative care medicines prescribed and the stock you hold | 12 (5.5) | 36 (17) | 76 (35) | 79 (36) | 14 (6.5) |
Limit your stock of palliative care medicines because ‘use by’ dates are likely to expire | 27 (12) | 37 (17) | 47 (22) | 67 (31) | 40 (18) |
Limit your stock of palliative care medicines because of lack of storage space | 63 (29) | 59 (27) | 38 (18) | 41 (19) | 15 (6.9) |
Experience problems receiving prescriptions electronically from patients’ GP practices | 28 (13) | 40 (18) | 65 (30) | 51 (23) | 34 (16) |
Encounter carers not having satisfactory ID, seeking to collect Controlled Drug prescriptions for patients | 16 (7.3) | 68 (31) | 73 (33) | 51 (23) | 10 (4.6) |